Arbor Biotechnologies uses AI and machine learning to develop gene editing therapeutics that aim to treat genomic diseases. Their current pipeline focuses on liver and Central Nervous System (CNS) diseases. Arbor Biotechnologies was founded in 2016 by David Scott Ph.D., Winston Yan Ph.D., David Walt Ph.D., and Feng Zhang Ph.D. and is headquartered in Cambridge, MA.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
09/27/2024 | Series C | $100MM | $xx.xx | $262.55MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
24,330,901
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Undisclosed Investors
|
||||||
11/09/2021 | Series B | $215MM | $xx.xx | $573.09MM | Temasek, Ally Bridge Group, TCG Crossover, Arrowmark Partners, Deep Track Capital, Great Point Ventures, Illumina Ventures, Janus Henderson Investors, Logos Capital, Ono Venture Investment, Piper Heartland Healthcare Capital, Ridgeback Capital Investments, Section 32, Surveyor Capital, T. Rowe Price Associates, Tao Capital Partners, Tekla Capital Management, Woodline Partners LP, Vertex Pharmaceuticals, ARCH Venture Partners | |
Price per Share
$xx.xx
Shares Outstanding
12,975,254
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Temasek, Ally Bridge Group, TCG Crossover, Arrowmark Partners, Deep Track Capital, Great Point Ventures, Illumina Ventures, Janus Henderson Investors, Logos Capital, Ono Venture Investment, Piper Heartland Healthcare Capital, Ridgeback Capital Investments, Section 32, Surveyor Capital, T. Rowe Price Associates, Tao Capital Partners, Tekla Capital Management, Woodline Partners LP, Vertex Pharmaceuticals, ARCH Venture Partners
|
||||||
05/19/2017 | Series A | $16.6MM | $xx.xx | $27.67MM | ARCH Venture Partners | |
Price per Share
$xx.xx
Shares Outstanding
8,887,460
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
ARCH Venture Partners
|